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ABSTRACT
Ectopic expression of the double homeodomain tran-
scription factor DUX4 causes facioscapulohumeral
muscular dystrophy (FSHD). Mechanisms of action
of DUX4 are currently unknown. Using immortalized
human myoblasts with a titratable DUX4 transgene,
we identify by mass spectrometry an interaction be-
tween the DUX4 C-terminus and the histone acetyl-
transferases p300/CBP. Chromatin immunoprecip-
itation shows that DUX4 recruits p300 to its tar-
get gene, ZSCAN4, displaces histone H3 from the
center of its binding site, and induces H3K27Ac in
its vicinity, but C-terminal deleted DUX4 does not.
We show that a DUX4 minigene, bearing only the
homeodomains and C-terminus, is transcriptionally
functional and cytotoxic, and that overexpression
of a nuclear targeted C-terminus impairs the ability
of WT DUX4 to interact with p300 and to regulate
target genes. Genomic profiling of DUX4, histone
H3, and H3 modifications reveals that DUX4 binds
two classes of loci: DNase accessible H3K27Ac-
rich chromatin and inaccessible H3K27Ac-depleted
MaLR-enriched chromatin. At this latter class, it acts
as a pioneer factor, recruiting H3K27 acetyltrans-
ferase activity and opening the locus for transcrip-
tion. In concert with local increased H3K27Ac, the
strong H3K27Ac peaks at distant sites are signifi-
cantly depleted of H3K27Ac, thus DUX4 uses its C-
terminus to induce a global reorganization of H3K27
acetylation.
INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD) is a dev-
astating muscular dystrophy that affects more than 25 000
people in the United States. The disease is caused by altered
chromatin on the D4Z4 macrosatellite repeats at 4q35.2
(1–4), which leads to transcription from these repeats. The
altered chromatin is typically caused by unit array con-
tractions reducing array size to <11 repeats (5,6), but in
rare cases is caused by mutation of the SMCHD1 gene (7).
The D4Z4 transcript encodes a double-homeodomain tran-
scription factor, DUX4 (8,9). Although difficult to detect in
human cells and tissue samples (10–12), DUX4 is neverthe-
less thought to be responsible for the pathology observed in
FSHD, in part because FSHDonly occurs whenD4Z4 con-
tractions occur on alleles that provide the DUX4-encoding
RNA with a functional polyA signal (13), and in part be-
cause DUX4 has pathological effects on myogenic cells, in-
ducing oxidative cell death at high levels of expression, and
inhibiting MyoD and impairing myogenesis at low levels of
expression (14).
The DUX4 protein has two conserved domains: the
DNA-binding tandem homeodomains at the N-terminus
of the protein which bind a sequence related to TAATC-
TAATCA (15,16), and the less conserved C-terminal do-
main (17) which confers transcriptional activation poten-
tial onGal4 (18). Variants of DUX4 lacking the C-terminus
are no longer cytotoxic (19), and lose the ability to upregu-
late DUX4 target genes (15), further suggesting that the C-
terminus is a transcriptional activation domain. However,
the mechanism of transcriptional activation by DUX4 is
unknown.
The C-terminal domain contains acidic amino acid
residues that are commonly found in other transactiva-
tion domains. However, apart from this, the sequence of
DUX4 is not conserved with other known transactivators.
Therefore, it is unclear whether DUX4 acts as a conven-
tional transcription factor, recruiting co-activators or co-
repressors to binding sites to alter chromatin structure,
thereby regulating the activity of RNA pol II (20). DUX4
protein complexes or cofactors have not been described. In
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this study, we identify p300 and CBP, related co-activators
with histone acetyltransferase activity (21), as factors that
interact withDUX4 and are recruited to target genes at sites
of DUX4 binding. We find H3K27 acetylation peaks flank-
ing genomic DUX4 target loci within 6 hours of DUX4
expression, map the p300 interaction to the C-terminus of
DUX4 and investigate interfering with this interaction as a




FUGW-rtTA was generated by ligating PCR amplified
rtTA2(s)-m2-ires-GFP into BamH1/EcoR1 FUGW (22).
The Dox-inducible DUX4 lentivector (pSam2-iDUX4-
Flag-UBC-puro) was generated as follows: The SV40 ploy
A signal was amplified from p2lox plasmid (23) and
cloned into the Not1 site of pSAM2 (24), which con-
tains a second generation tet-response element. The Pac1
to BsrG1 sequence of the plasmid was then replaced with
a Pac1/BsrG1 fragment containing the Ubiquitin C pro-
moter and EGFP from FUGW (22). Using In-Fusion
HD cloning (Clontech), GFP was then replaced with a
PCR fragment containing the puromycin resistance gene
(N-acetyl-transferase, PAC) to generate pSam2-Ubc-Puro.
An EcoRI/NotI PCR fragment encoding DUX4-flag was
ligated into EcoR1/Not1 sites of pSam2-Ubc-puro plas-
mid to generate pSam2-iDUX4-Flag-Ubc-Puro. The dox-
inducible C-terminally deleted DUX4 construct was con-
structed by replacing the EcoRI/NotI fragment with a
PCR fragment encoding DUX4C-Flag. The codon op-
timized DUX4-flag for bacterial expression was synthe-
sized (Biomatik) and ligated into KpnI/NotI digested
pMSCG10 (25). NLS-GFP-DUX4 fusion expression con-
structs were generated by ligating PCR amplified EGFP
into NheI/EcoRI digested IRESpuro3 plasmid (Clontech),
to generate pIRESpuro3-EGFP. DUX4-F1, DUX4-F2,
and DUX4-F3 were generated by In-Fusion cloning (Clon-
tech) and ligated into EcoRI/AgeI digested pIRESpuro3-
EGFP. EGFP-NLS was amplified by PCR and replaced
EGFP for control plasmid. To generate EGFP-NLS-
DUX4-C98, the C-terminus of DUX4 was amplified by
PCR and ligated to EcoRI/AgeI digested pIRESpuro3-
EGFP. The regulatory elements of the ZSCAN4 gene were
amplified by PCR and ligated into Nhe1/Xho1 digested
pGL3 basic (Zscan4-luc). Primer sequences are provided in
Supplemental Table S1.
Generation of doxycycline-inducible DUX4 cells
The immortalized human myoblast line LHCN-M2 (26),
kindly provided by Vincent Mouly, were transduced with
two lentivectors, the first (FUGW-rtTA) expressing the re-
verse tetracycline transactivator rtTA2m2 together with an
IRES-EGFP from the human Ubiquitin C promoter. To
generate lentiviral supernatants, 293T cells were transfected
with vector plasmid, packaging (psPAX2) and envelope
(pMD2.G) plasmids. Fourty eight hours post-transfection,
media was collected and lentivirus was concentrated using
ultracentrifugation, and cells were transduced in the pres-
ence of 10 g/ml polybrene. GFP+ cells were sorted af-
ter the first transduction, then transduced with the second
vector, which carried flag-tagged DUX4 under the control
of the second-generation tetracycline response element (27)
with a Puro-resistance gene (Figure 1A). After puromycin
treatment, cells were individually sorted into 96-well dishes,
and three independent clones were isolated and evaluated.
Immunoprecipitation and mass spectrometry
109 LHCN-M2-iDUX4-flag cells were prepared in the ab-
sence or presence of doxycycline (500 ng/ml) for 6 h. Cells
were washed twice with PBS, harvested, and nuclear extract
was prepared as described (Dignam et al., 1983). Briefly,
cells were lysed in hypotonic solution, low salt buffer,
and high salt buffer and nuclear extract was treated with
Benzonase nuclease (Sigma) (van den Berg et al., 2010).
Nuclear extract was dialyzed in BC300 and precleared
withmouse IgG-agarose beads (Sigma). Pre-cleared nuclear
lysate was immunoprecipitated with Anti-flagM2-magnetic
beads (Sigma) and extensively washed with BC300 (20 mM
Tris, 20% glycerol, 0.2mM EDTA, 300mM KCl) contain-
ing 0.1% NP-40. Immunoprecipitates were eluted with flag
peptides (Sigma) and 5% of eluted samples were tested by
SDS-PAGE and visualized with silver staining (Pierce). The
remaining samples were used for mass spectrometry anal-
ysis performed at the Taplin Biological Mass Spectrome-
try Facility at Harvard Medical School. To validate DUX4
interacting proteins, western blot analysis was performed
with following antibodies : DUX4 (abcam; ab124699), Flag
(Sigma; F1804), Flag-HRP (Sigma; A8592), p300 (Milli-
pore 05-257 and Santa Cruz; sc-584), CBP (Santa Cruz; sc-
369),GAPDH-HRP (GenScript; A00192), andGFP (Santa
Cruz; sc-8334).
DUX4 protein purification and GST-pull down
Codon optimized GST-TEV-DUX4-Flag in pMCSG10
was expressed in Rosetta2 pLysS strain E. coli. First, C-
terminal flag epitope tagged DUX4 was purified using flag
peptide elution (Gu and Roeder, 1997). Briefly, 3 h after
0.1 mM IPTG induction, E. coli was lysed in lysis buffer
(500 mMNaCl, 20 mMTris, 10% glycerol, 0.2 mMEDTA).
DUX4-Flag was immunoprecipitated with anti-flag M2-
magnetic beads (Sigma) andwashed extensivelywithBC300
containing 0.1% NP-40. DUX4-flag was eluted with flag
peptide (Sigma) in BC100 (20 mM Tris, 20% glycerol, 0.2
mM EDTA, 100 mM KCl) solution. GST-only control or
GST-DUX4-flag was purified again with glutathione mag-
netic beads (Pierce) and GST or GST-DUX4-flag and a
recombinant p300 protein (Millipore) were incubated in
NETN buffer (100 mM NaCl, 1 mM EDTA, 20 mM Tris–
HCl, pH8.0, and containing 0.5% detergent NP-40) (Kim
et al., 2003). After washing, bound proteins were analyzed
by immunoblot with anti-p300 antibody.
Cell viability assay
Cell viability assay was performed as described
(Bosnakovski et al., 2014). Cells were treated with
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doxycycline for 48 h and cell viability was measured using
the CellTiter-Glo luminescent assay based on quantitation
of ATP (Promega). Briefly, the plates were equilibrated at
room temperature and media was removed. CellTiter-Glo
reagent diluted (1:1) in PBS was added and the plates were
read in a Cytation3 plate reader (BioTek).
Chromatin immunoprecipitation and ChIP-qPCR/ChIP-seq
analysis
ChIP assays were performed according to previously de-
scribed protocol with slight modifications (Boyer et al.,
2005). The sonicated chromatin was incubated with the in-
dicated antibodies overnight at 4◦C followed by incubation
with 30 l of Magna ChIP Protein A+G magnetic beads
(Millipore) for 2 h. ForChIP andChIP-seq experiments, the
following antibodies were used: Flag (Sigma; F1804), p300
(Santa Cruz; sc-584), H3 (abcam; ab1791), H3K18Ac (ab-
cam; ab1191), H3K27Ac (abcam; ab4729), and H3K4me3
(abcam; ab8580). Beads were washed with RIPA buffer and
TE buffer containing 50 mM NaCl. The immunoprecipi-
tated complexes were eluted from the beads by heating at
65◦C and reverse crosslinked by overnight incubation at
65◦C. ImmunoprecipitatedDNAwas treated withRNaseA
and proteinase K. The immunoprecipitated DNA was pu-
rified using a PCR purification kit (Qiagen) and quantified
by qPCR using SYBR Premix Ex Taq (Clontech) according
to the manufacturer’s instructions. All primers for ChIP-
qPCR are shown in Supplemental Table S1. All reactions
were performed in a two-step PCR condition (95◦C for 15
s and 60◦C for 30 s) using Applied Biosystems 7500 Real-
time PCR system (Applied Biosystems) and the quantifi-
cation cycle (Cq) was determined by default settings. Each
PCR reaction was tested with a melting curve analyses to
confirm the specificity of the amplification and the absence
of primer dimers. All data were converted to relative values
based on a standard curve and normalized to 1% input val-
ues of the same sample. Primers are listed in Supplemental
Table S1.
For ChIP-seq, inputs and immunoprecipitates were used
to create libraries as follows: Blunt end repair of ChIPed
DNAwas performed using End-it DNA repair kit (Epicen-
tre, ER0720) and ‘A’ basewas added to 3′ ends usingKlenow
Fragment (3′→5′ exo-) (NEB, M0212). NEXTflexTM DNA
Barcodes (BIOO Scientific, 514103) were ligated to DNA
fragments using LigaFastTM Rapid DNA Ligation Sys-
tem (Promega, M8221) and 200–500 base pair DNA was
selected using Agencourt AMPpure XP (Beckman Coul-
ter, A63881). 15 cycles of PCR amplification were per-
formed using Phusion High-Fidelity PCRMasterMix with
HF Buffer (ThermoFisher Scientific, F531S). Fifty base
pairs of DNA sequence were read from a single end on
a HiSeq 2000/2500 (Illumina) by the University of Min-
nesota Genomics Center. Read sequences were trimmed
(Trimmomatic 0.32), mapped to the hg19 genome (Bowtie
2) and sorted (Samtools 1.2) at the University of Min-
nesota Supercomputing Institute. Peaks were identified
(MACS 1.4) and analyzed with custom R scripts (28) avail-
able at https://github.com/micahgearhart/dux4. DNase-Seq
data for LHCN-M2 cells was obtained from the ENCODE
project accession ENCFF001BVR. Sequencing data have
been deposited in the Gene Expression Omnibus repository
under accession code GSE78158.
LHCN-M2 RNA-Seq
Total RNA was harvested from 6 independent cultures of
LHCN-M2iDUX4 cells, three of which were treated with
250 ng/ml dox for 6hrs. Libraries were created by the Uni-
versity of Minnesota Genomics Center from the polyA+
mRNAs using the TruSeq RNA library preparation kit.
Fifty bp paired-end sequence was obtained and trimmed as
above. Paired-end reads were mapped to GRCh37 genome
(Star 2.4) and uniquely mapped reads were assigned to
genes using the Ensembl version 75 annotation. Differential
expression was determined with DESeq2 (29) using custom
R scripts available at https://github.com/micahgearhart/
dux4.
DUX4 reporter assay
293T cells were transfected using TansIT-LT1 (Mirus) ac-
cording to manufacturer instructions.
Briefly, 293T cells were transfected with a DUX4 re-
porter construct, Renilla luciferase ZSCAN4-Luc (firefly
luciferase under the control of the regulatory elements of
the ZSCAN4 gene) together with pCI-neo empty vector
(EV) or pCI-neo-DUX4 in combination with the indicated
DUX4 fragments. Cells were lysed 24 h post-transfection in
Passive Lysis Buffer (Promega). Luciferase activities were
quantified using reagents from the Dual-Luciferase Re-
porter Assay System (Promega) following manufacturer’s
instructions. Light emission was measured using on a Cy-
tation3 plate reader (BioTek). The ratio of firefly/Renilla
luciferase data was calculated and given as the averages ±
SD of at least triplicates.
Gene expression analysis
293T-iDUX4 cells were transiently transfected with
control or the indicated DUX4 fragments and 24 h post-
transfection cells were treated with doxycycline for 6 h to
induce WTDUX4. Immortalized myoblast cells expressing
dox-inducible DUX4-C or DUX4 (three independent
clones of each) were also treated with doxycycline for 6
h. Total RNA was extracted from around 1 × 106 fresh
cells using RNeasy mini kit (Qiagen) and genomic DNA
was removed by RNase-free DNase (Qiagen). Reverse
transcription (RT) was performed using the Vero cDNA
synthesis kit (Thermo Scientific) and quantitative poly-
merase chain reactions (PCR) were performed using
Premix Ex TaqTM,ROX Plus (Clontech) and hydrolysis
(Taqman) probes (ZSCAN4; Hs00537549 m1, MYF5;
Hs00271574 m1, MYOD1; Hs00159528 m1, CCNA1;
Hs00171105 m1, GAPDH; Hs99999905 m1) (Applied
Biosystems). Reactions were performed as described above
for ChIP-qPCR experiments. The data were normalized to
the reference gene GAPDH and relative mRNA expression
was calculated by the Cq method. Gene expression data
are given as the averages ± SD of at least triplicates.
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Figure 1. DUX4 interacts with p300/CBP. (A) Schematic diagram of the lentiviral constructs carrying doxycycline-inducible DUX4 and rtTA. sgTRE:
second generation tet-response element for doxycycline-induced expression. (B) Immunoblot showing doxycycline dose-dependent inducible expression
of DUX4-flag in LHCN-M2 cells. (C) Time course of induction of DUX4 downstream target genes, FRG2 and ZSCAN4. (D) Cell death of immortalized
human LHCN-M2 myoblasts 48 hours after DUX4 induction with 250 ng/ml doxycycline. (E) Silver stained SDS-PAGE gel of DUX4-flag associated
proteins, 6 h after 250 ng/ml doxycycline treatment. (F) Immunoblots of DUX4-associated factors, p300 and CBP, in immunoprecipitates with Flag-
DUX4. (G) Direct interaction of DUX4 with p300. Left panel: Coomassie staining of GST and GST-DUX4 proteins purified from E. coli. Right panel:
immunoblot for recombinant p300 after GST-pull down, showing interaction with GST-DUX4 but not GST alone.
RESULTS
Doxycycline-inducible DUX4-expressing human myoblasts
In order to study the activity of DUX4 in human myogenic
cells, we engineered an immortalizedmyoblast line (26) with
lentivectors for doxycycline (dox)-inducible expression of
flag-tagged DUX4 (Figure 1A). In these cells, DUX4 is ex-
pressed within 2 h (Figure 1B), target genes are strongly up-
regulated by 6 h (Figure 1C), and cells die within 24 h of 250
ng/ml dox (Figure 1D), similar to what has been observed
in the murine system (14,30).
DUX4 interacts with p300 and CBP
To identify proteins that interact with DUX4, we immuno-
precipitated DUX4 from nuclear extracts prepared from
cells exposed to dox (500 ng/ml) for 6 hours or control cells
not exposed to dox. Flag immunoprecipitated extract con-
tainedDUX4andmultiple dox-dependent (DUX4-specific)
proteins (Figure 1E).We performedmass-spectrometry and
identified potential interacting proteins. Of these, CBP was
the protein with the greatest number of unique reads, and
its homologue p300 had the third most reads, with no other
coactivators in the top 10most-read sequences (Supplemen-
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tal Figure S1 shows sequence coverage of p300 and CBP).
We then confirmed both p300 and CBP interactions by
independent co-immunoprecipitation experiments (Figure
1F). To further confirm the interaction ofDUX4with p300,
we tested the ability of GST-DUX4 versus GST control to
pull down recombinant p300 protein (Millipore). This re-
vealed a specific interaction between p300 and GST-DUX4
(Figure 1G).
TheC-terminus ofDUX4 is required for interactionwith p300
and transcriptional upregulation
The DUX4C gene, which encodes a version of DUX4 with
an alternate C-terminus replacing the C-terminal 82 amino
acids, does not induce cell death when overexpressed (19)
and a short form of DUX4 that does not contain C-
terminus did not have the ability to upregulateDUX4 target
genes (15), suggesting that the C-terminus of DUX4 is the
transactivation domain, and perhaps the domain that inter-
acts with p300. First, to definitively delineate the transacti-
vation domain(s) of DUX4, we created internal deletions
of various sizes, the largest retaining only the last 53 amino
acids (Figure 2A), which is the unique region of conserva-
tion with DUXC family members (17). We tested the tran-
scriptional activity of each deletion mutant by measuring
expression of ZSCAN4, a strong DUX4 target gene (15)
(Figure 2B). The smallest construct with only 52 amino
acids, DUX4-F1, only weakly induced the DUX4 reporter,
while DUX4-F2 and DUX4-F3 which contain 98 and 144
amino acids of the C-terminus, respectively, induce ZS-
CAN4 expression just as well as full length DUX4. The
toxicity of these constructs correlated with their activation
potential, i.e. constructs with 98 amino acids or more of
C-terminal sequence were highly and equally toxic (Fig-
ure 2C). Thus, a minigene containing the homeodomains
and the C-terminal 98 amino acids of DUX4 is functionally
equivalent to full lengthDUX4. To further examine the role
the C-terminus, we generated immortalizedmyoblast clones
expressing dox-inducible DUX4-C, which lacks the C-
terminal 98 amino acids (Figure 3A). We compared expres-
sion levels of DUX4 and DUX4-C (three independent
clones of each) and found that DUX4-C was expressed at
much higher levels than DUX4 (Figure 3B), an effect that
we attribute to a post-transcriptional mechanism.While FL
DUX4 precipitated both p300 andCBP,DUX4-Cdid not
(Figure 3C), indicating that the C-terminus of DUX4 is es-
sential for interaction with these coactivators, and provid-
ing an explanation for the lack of transcriptional activity
of C-terminal deletion forms of DUX4. To verify the lack
of transcriptional activation, we examined the expression
level of several DUX4 target genes in DUX4 and DUX4-
C myoblasts 6 h after doxcycline treatment. Genes that
are upregulated by DUX4 (ZSCAN4 and CCNA1) were
not upregulated by DUX4-C (Figure 3D). On the other
hand, genes that are downregulated by DUX4 (MYF5 and
MYOD1) were also downregulated by DUX4-C, indicat-
ing that the C-terminus participates in transcriptional acti-
vation but not transcriptional repression. These studies de-
fine the last 98 amino acids of DUX4 as necessary for in-
teraction with p300 and sufficient for full upregulation of
DUX4 target genes.
FL DUX4 recruits p300 and drives epigenetic changes at
ZSCAN4
Because p300 has histone acetyltransferase activity, its re-
cruitment by DUX4 would be expected to result in in-
creased H3K18Ac and H3K27Ac marks in regions near
DUX4 binding sites (31). We therefore tested for presence
of DUX4, p300, and a variety of histone H3 marks in dif-
ferent regions of one of the most responsive DUX4 target
genes, ZSCAN4. Previous ChIP-seq data revealed a DUX4
peak in the annotated second exon of ZSCAN4 (15). We
prepared chromatin from both DUX4- and DUX4-C-
inducible immortalized myoblasts 6 h after dox treatment,
performedChIPwith antibodies to Flag (DUX4) and p300,
and assayed the annotated promoter region as well as exon
2 of ZSCAN4 (Figure 4A). As expected, we found that the
exon 2 site was robustly pulled down by Flag (DUX4) anti-
bodies. We did not observe enrichment of DUX4 at the an-
notated ZSCAN4 promoter. Similarly, DUX4-C was en-
riched specifically at the exon 2 site and not at the promoter
(Figure 4B). We then evaluated p300, and found robust en-
richment at both the promoter region and at exon 2, but
only in the inducibleDUX4 cells, not in theDUX4-C cells
(Figure 4C). These data show that when FL DUX4 binds,
p300 is recruited, but when DUX4C binds, p300 is not
recruited, in agreement with the data above, demonstrating
that the C-terminus is the p300 interaction domain.
To evaluate epigenetic marks, we first tested enrichment
with total histone H3 and found that H3 was relatively de-
pleted from the exon 2 regionwhenDUX4was present (Fig-
ure 4D). This depletion was seen only weakly with DUX4-
C. This data suggests that binding of FL DUX4 displaces
nucleosomes, at least at this specific site. We then immuno-
precipitated with antibodies to H3 marks: K18Ac, K27Ac
and K4me3 using H3 occupancy to normalize the H3 mod-
ifications. This revealed that H3K18ac and H3K27ac were
enhanced at sites where and under conditions when p300
was present (Figure 4E and F). In addition, we found en-
hancement of H3K4me3 (Figure 4G), a histonemark found
in actively transcribed genes.
Global analysis of DUX4-induced changes at target loci
These data prompted us to investigate DUX4 effects on
H3K27Ac globally, with the aim of understanding the aver-
age or typical response of a generic DUX4 target locus. We
therefore performedChIP-seq onDUX4 (Flag), H3K27Ac,
H3K4me3, total H3 and RNA-seq, all at 6 h post-DUX4
induction via dox in the immortalized LHCN-M2 DUX4-
inducible myoblasts. Before generalizing, we first reviewed
this data over theZSCAN4 locus. H3K27Ac andH3K4me3
changes at ZSCAN4 were as predicted by Figure 4 above,
however the RNA-seq data clearly showed that in these
cells, ZSCAN4 transcription was initiated from an alterna-
tive promoter to produce a transcripted annotated in EN-
SEMBL as ENST00000612521. The DUX4 binding site,
presumed to be in exon 2, is in fact just upstream of the in-
duced transcript (Figure 5A). A clear peak for DUX4 was
observed at this site, and in the presence of this peak, a
strong H3K27Ac signal was induced immediately up and
downstream. The region under the DUX4 peak itself was
depleted for H3K27Ac signal, concordant with the total H3
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Figure 2. The central unstructured domain of DUX4 is dispensable for transcriptional activation and cytotoxicity. (A) Scheme of DUX4 deletion mutants.
HD: homeodomain. GFP was added to visualize DUX4 fragments. The number of DUX4 amino acids in the N-terminal and C-terminal parts of each
construct are indicated. (B) RT-qPCR analysis of RNA of the target gene ZSCAN4 after transient transfection of each construct. Protein expression levels
of DUX4 deletion mutants are shown by immune blot, below. (C) Viability of C2C12 cells expressing different levels of each DUX4 deletion mutant. All
constructs were targeted into the same genomic inducible locus. Cell viability (ATP content) was measured 24 h after treatment with doxycycline.
depletion at this site shown above in Figure 4D. The induced
acetylation ranged for several kb both upstream and down-
stream and encompassed the annotated promoter of ZS-
CAN4. Globally, we identified 31 042 DUX4 peaks, 17%
of which are in common with similar analysis of a previous
DUX4 ChIP-seq data set (15).
Globally, sites recognized by DUX4 showed much
greater H3K27Ac in the presence of DUX4 than in the
absence (Figure 5B), and although most sites showed low
acetylation prior to binding, there was clearly a population
of sites that were already acetylated, prior to DUX4 bind-
ing. The average pattern of acetylation across the region
bound by DUX4 showed a volcano shape, with the dip in
H3K27Ac in center of the DUX4 peak consistent with nu-
cleosome depletion at the site of DUX4 binding, however,
this dip was also present prior to binding, suggesting that
at a large subset of sites, nucleosomes are already depleted
(Figure 5C).
DUX4 binds two classes of target site: accessible and inac-
cessible
The presence of prior acetylation and a central dip in
H3K27Ac prior to DUX4 binding were unexpected and
prompted us to investigate the prior accessibility of DUX4
target loci. ENCODE data on global DNaseI hypersensi-
tivity in the same LHCN-M2 immortalized myoblast line
revealed that 12 919 DUX4 target loci are in DNase ac-
cessible sites, while 18 107 are inaccessible prior to DUX4
binding. We therefore analyzed ChIP-seq data indepen-
dently for these two classes of site. The accessible sites were
histone-depleted before DUX4 binding and remained so
after, while the inaccessible sites showed histone depletion
only after DUX4 binding (Figure 5D, second row and Sup-
plemental Figure S2A). The inaccessible sites showed very
low prior acetylation that was greatly elevated by DUX4
binding, while acetylation changes at accessible sites were
less dramatic (Figure 5D, third row, and Supplemental Fig-
ure S2A). The H3K4me3 mark behaved broadly similarly,
present prior to binding at accessible sites and increased
greatly after binding at inaccessible sites, which is consis-
tent with the doxyclycline dependent enrichment at the E2
site in ZSCAN4 (Figure 4G) and may reflect the activation
of nearby genes via the recruitment of histone methyltrans-
ferases. In theDNase-inaccessible subset, there was actually
a depression inH3K27Ac andH3K4me3 at the center of the
region. This is due to the fact that although theDUX4 bind-
ing site at the core of each of these regions is DNase inacces-
sible, in some regions there are flanking DNase accessible
sites, which are associated with local increased H3K27Ac
and H3K4me3. If such regions are eliminated from anal-
ysis, the profile is flat (Supplemental Figure S2B). An fur-
ther interesting feature of the DNase inaccessible set is that
this is where the great majority of MaLR (mammalian ap-
parent long terminal repeat)-containing DUX4 peaks are
contained (Figure 5E). These data suggest that DUX4 can
function as a pioneer factor, able to bind at sites within con-
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Figure 3. The C-terminal domain of DUX4 is required for p300 interaction and DUX4-mediated transcriptional activation, but not for repression of
target genes. (A) Schematic diagram of DUX4-C and full length DUX4. The C-terminal 98 amino acids were deleted in DUX4-C. (B) Western blots
indicating the level of DUX4-C and DUX4 expression in three independent LHCN-M2 clonal cell lines. Whole cell lysates were prepared after 6 h of
dox treatment. Note that the C-terminal deletion is expressed much more abundantly. (C) p300/CBP binds to the C-terminal domain of DUX4. DUX4-
C-flag and DUX4-flag were immunoprecipitated with flag antibody 6 h after 250 ng dox treatment. Endogenous p300 and CBP were coprecipitated
with DUX4-flag, but not with DUX4-C-flag. (D) RT-qPCR analysis of two upregulated genes (ZSCAN4 and CCNA1), and two downregulated genes
(MYOD1 and MYF5) in DUX4-C or DUX4 inducible LHCN-M2 cells 6 h after 250 ng/ml dox treatment. Expression is normalized to GAPDH (n =
3, three independent clones, error bars represent SEM, t-test: ***P< 0.001 versus no dox group). Note that the C-terminus is necessary for activation, but
dispensable for downregulation ofMYOD1 andMYF5.
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Figure 4. p300 is recruited to the DUX4 binding site in ZSCAN4. (A) Location of PCR amplicons in the ZSCAN4 gene used for ChIP analyses. The
previously-identified DUX4-binding site is at +1430, in exon 2. (B–G) ChIP assays with various antibodies at the indicated ZSCAN4 loci (ZSCAN4-P:
promoter region, ZSCAN4-E: exon 2 region). LHCN-M2 cells were treated with 250 ng/ml dox for 6 h to express DUX4 or DUX4-C and subjected to
ChIP analyses.% input of H3K18Ac, H3K27Ac, and H3K4me3 were normalized with% input of H3 (n = 3, error bars represent SEM). Note that both
DUX4 and DUX4C are recruited to the DUX4 site in exon 2, but p300 is not recruited by DUX4C, and acetylation of H3K18 is not increased by
DUX4C.
formationally inaccessible chromatin that are replete with
histones lacking markers of activation, and thereafter re-
cruits histone acetyl- andmethyl-transferases to enable gene
expression.
We wondered what effect DUX4 recruitment of H3K27-
acetyltransferase activity would have at sites not associated
with DUX4 but previously acetylated. We therefore identi-
fied all H3K27Ac peaks not associated with DUX4 (both +
and – dox) and evaluated levels of enrichment before and af-
ter DUX4 expression. This showed a loss of regions of very
high acetylation and a general narrowing of the H3K27Ac
profile after DUX4 expression (Figure 6A). Stacking of all
non-DUX4 associated H3K27Ac peaks revealed that al-
though most prior-acetylated peaks retain a signal of acety-
lation, there is great reduction in intensity, and in addition,
a significant number of new peaks form (Figure 6B). New
H3K27Ac peaks not associated with DUX4 may be indi-
rect, i.e. secondary, DUX4 targets, or may be DUX4 targets
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Figure 5. Genome wide changes in histone H3 andH3K27ac occupancy byDUX4 in LHCN-M2-iDUX4 cells. (A) Pan-histone H3 andH3K27Ac changes
at ZSCAN4 after DUX4 expression. Red and black ovals represent the TAATTCAATCA and TAAATCAATCA DUX4 homeodomain binding mo-
tifs respectively. A strong DUX4 peak, shown in blue, is observed at these motifs proximal to an alternate promoter for ZSCAN4 (Ensembl Transcript
ENST00000612521); pan-Histone H3 signal before (–) and after (+) doxycycline treatment are shown in green; H3K27Ac signals before and after doxy-
cycline are shown in red. Note the loss of histone H3 signal and the appearance of H3K27Ac peaks that form adjacent to the site of DUX4 binding. (B)
Genome wide changes in chromatin upon DUX4 induction. The distribution in the number of sequence reads in the H3K27ac datasets that map to within
1 kb of 31 042 Dux4 peak summits is shown as a violin plot in absence or presence of doxycycline. (C) The ChIP signals 4 kb upstream and downstream
of the peak summits were summed across all Dux4 binding sites, normalized to the mapped sequencing depth and log2 transformed. The upper panel
contains reads for the input (yellow) and Flag-DUX4 ChIP (blue) samples. The lower panel contains the H3K27Ac ChIP signals that were observed before
(orange) and after (blue) doxycycline treatment. (D) The regions bound by DUX4 used in panels (B) and (C) were separated into 12 912 peaks that overlap
DNase hypersensitivity sites (left panels) and 18 130 peaks that do not (right panels). ChIP signals are shown for input, Flag-DUX4 ChIP, histone H3
ChIP, H3K27Ac ChIP and H3K4me3 ChIP. Data are colored as in panel C: input = yellow, absence of doxycycline = orange, presence of doxycycline
= blue. Note that a decrease is observed in the histone H3 signal upon DUX4 induction in the DNase in-accessible regions and that a similar decrease
preexisted in the DNase accessible DUX4 binding regions. A saddle-shaped distribution of H3K27Ac ChIP signal is observed at DUX4 peaks at DNase
accessible regions and upon DUX4 induction in DNase in-accessible regions.
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Figure 6. Global changes in H3K27Ac distribution lead to direct and indirect gene expression changes in LHCN-M2-iDUX4 cells. (A) Redistribution in
the number of sequence reads from the H3K27Ac ChIP signals at 68 506 equal width genomic loci that are enriched for H3K27Ac signal in either the
absence or presence of doxycycline but are not bound by detectable levels of DUX4 is shown as a violin plot for both conditions. (B) A heatmap view of the
regions in panel A sorted by the ratio of signal observed in the absence or presence of doxycycline. The top and bottom of the heatmap contains regions
that have a marked increase or decrease in H3K27Ac upon Dux4 expression respectively. (C) Differential gene expression upon DUX4 induction. Minus
log10p-values are plotted against the log2 fold change between the control and doxycycline treated samples. The points are colored according the nearest
distance between the transcription start site to a DUX4 peak: overlapping (yellow), <5 kb (blue), <10 kb (red), <50 kb (pink) and > 50 kb (gray). The
lower panels indicate whether the DUX4 peak associated with each gene (<50 kb) is in a DNase Accessible (middle panel) or DNase In-Accessible region
(lower panel). Note that genes with very high expression changes are associated with DUX4 peaks in DNase In-Accessible Regions.
whose peaks were weak andmissed by our algorithm. These
data demonstrate a large scale reallocation of H3K27Ac
across the genome after DUX4 expression, with a partic-
ular reduction in the strongest peaks.
RNA-seq identified a large set of gene expression changes
in response to DUX4, both up- and down-regulation, how-
ever the majority of strongly upregulated genes were in the
vicinity of a DUX4 peak (colored dots, Figure 6C, top).
When those changes associated with a DUX4 peak were
subdivided by prior accessibility of the DUX4 target locus,
upregulation was seen at both accessible and inaccessible
loci, but the most strongly upregulated genes were in the
prior inaccessible set (Figure 6C bottom panel).
Dominant negative activity of the DUX4 C-terminus
Because of the clear induction of H3K27 acetylation at sites
of DUX4 binding, and the interaction of the DUX4 C-
terminus with p300/CBP, we wondered whether compet-
ing away this interaction from full length DUX4 by over-
expressing the DUX4 C-terminus would affect the ability
of DUX4 to induce transcription. To test this, we gener-
ated a 293T derivative with inducible full length DUX4,
using the same lentiviral strategy described above, and
transfected these DUX4-inducible 293T cells with nuclear-
targeted GFP alone, or fused to the C-terminus of DUX4
(Figure 7A). Eight hours after transfection, we then induced
full length DUX4 expression with doxycycline and assayed
the endogenous DUX4 target gene, ZSCAN4. Transfec-
tion of the nuclear-targetedDUX4C-terminus inhibited the
DUX4-induced expression of endogenous ZSCAN4 (Fig-
ure 7B). It also inhibited expression of a cotransfected
ZSCAN4-luciferase reporter (Figure 7C), demonstrating
that the C-terminus does indeed have dominant negative ac-
tivity. Finally, to test whether this dominant negative activ-
ity involves the interferingwith the p300 interaction, we per-
formed co-IPs of FL DUX4 using the Flag antibody from
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Figure 7. Dominant negative activity of the p300 interacting C-terminal domain of DUX4. (A) Schematic of DUX4 expression constructs. 293T cells
modified to express full-length DUX4 driven from the dox-inducible sgTRE promoter, shown above, were transfected with transient expression constructs,
shown below. The number of C-terminal DUX4 amino acids is indicated. sgTRE: second generation tet-response element for dox-induced expression;
CMV: CMV promoter for high level constitutive expression; NLS: SV40-nuclear localization signal; HD: homeodomain. GFP was added to stabilize
DUX4 fragments. NLS was added to deliver DUX4 fragment in the nucleus. (B) DUX4 mediated ZSCAN4 mRNA expression. Cells were transfected,
24 h later 250 ng/ml dox was applied, and mRNA extracted 6 hours after that (n = 3, error bars represent SEM). (C) Activity of a cotransfected DUX4-
luciferase reporter. 293T cells were co-transfected with both full length DUX4 and empty vector (EV) or the tested fragments, together with DUX4
luciferase and Renilla control reporters (n = 3, error bars represent SEM). (D) Western blots of DUX4 immunoprecipitations performed in the presence
of GFP-NLS control or GFP-NLS-DUX4-C-terminal 98 amino acids. Interaction of full length DUX4 with p300 is inhibited by overexpression of the
C-terminus of DUX4.
cells overexpressing the GFP-NLS-C-terminus. Indeed, in
the presence of the overexpressed C-terminus, the interac-
tion of full length DUX4 with p300 was substantially di-
minished (Figure 7D). Together, these data suggest that the
DUX4 C-terminus exhibits dominant negative activity by
competing with full length DUX4 for p300/CBP.
DISCUSSION
Although target genes of DUX4 have been identified in
a number of studies (14,15,32), the mechanisms used by
DUX4 to drive these gene expression changes has not been
investigated. Our data show that p300 and CBP are DUX4
interacting proteins, that they interact with the DUX4 C-
terminus, and that they are recruited to upregulated tar-
get genes such as ZSCAN4, when DUX4 is bound. Both at
ZSCAN4 specifically, and across the genome at all DUX4-
bound regions, histone H3 is depleted from the central re-
gion of the DUX4 peak, suggesting that DUX4 binding
displaces nucleosomes. Consistent with this, approximately
60% of DUX4 bound regions were previously inaccessible
to DNaseI, but are bound by DUX4 nonetheless, and are
then centrally depleted of H3, suggesting that DUX4 can
act as a pioneer factor. Interestingly, in the 40% of sites that
were previously accessible to DNase, the central depletion
of H3 is present before binding, suggesting the presence of
other binding factors at these sites prior DUX4 binding.
The possibility that DUX4 is tethered to these sites by the
resident factors rather than by binding to DNA is unlikely:
the consensus DNA motif recognized by DUX4 (15) is
equally present in both classes of target site. H3K27Ac is in-
creased in the flanking regions of both classes of DUX4 tar-
get locus, but the increase is most pronounced at sites in pre-
viously inaccessible chromatin, as they showed prior deple-
tion of H3K27Ac. In addition to enrichment of H3K27Ac,
H3K4me3 is also locally enriched. This is consistent with
the idea that the acetylation activity of p300/CBP effects
epigenetic changes promoting gene activation by recruiting
histone methyltransferases such as the SET1 complex (33).
While the increase in acetylation in the vicinity of
DUX4 peaks was pronounced, the amount of depletion
of H3K27Ac at non-DUX4 associated sites of peak en-
richment prior to DUX4 expression was equally striking.
Transcriptional profiling showed downregulation of many
transcripts, almost exclusively within the set that were not
associated with DUX4 binding, but this downregulation
was modest compared to the upregulation of DUX4 tar-
gets. It is likely that the very short time between induction
of DUX4 and assay (6 h) combined with perdurance of
these transcripts explains their modest downregulation. Al-
though there has been much thought given to the poten-
tial role particular DUX4-induced target genes in the cy-
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topathology of DUX4 (9,14,15,34), it may well be the dis-
rupted expression of the large number of non-targets that
is the more lethal. However, it is important to keep in mind
that the level of expression of DUX4 in those FSHD cells
that do express it is unknown, and the global reductions in
the major H3K27Ac peaks described here may depend on
relatively high levels of DUX4.
We show that the C-terminus of DUX4 is essential for
the interaction with p300. It was previously reported that
a fusion protein combining the DNA binding domain of
CIC and the C-terminus of DUX4 acts as a transactiva-
tor to promote tumorigenesis (19). By deleting the middle
half of the DUX4 protein sequence, we show that the only
domains necessary for cytotoxicity and transcriptional ac-
tivation by DUX4 are the N-terminal DNA-binding home-
odomains and the C-terminal 98 amino acid transcriptional
activation domain.
The importance of the C-terminal domain is underscored
by the fact that it can act as a dominant negative. This dom-
inant negative activity is presumably due to the formation
of non-productive complexes of the C-terminus with coac-
tivators, depriving FL DUX4 of opportunities for produc-
tive interactions. Indeed, we find that the interaction of FL
DUX4 with p300 is greatly diminished in the presence of
the overexpressed C-terminus. This approach to inhibiting
DUX4 activity may open up avenues for therapy develop-
ment, particularly if the dominant negative activity can be
reduced to small peptides from the DUX4 C-terminus or
from p300 that would compete for this interaction, a strat-
egy that has been successful in other systems (35).
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